Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1992 Sep;35(5):302–306. doi: 10.1007/BF01741142

Penetration of anti-melanoma immunotoxin into multicellular tumor spheroids and cell kill effects

Takao Kikuchi 1,, Takao Ohnuma 1,, James F Holland 1, Lynn E Spitler 2
PMCID: PMC11041091  PMID: 1394334

Abstract

In order to gain a better understanding of the interaction between immunotoxins and tumor cells at the level of three-dimensional tumor mass, we evaluated the cell kill effects of monoclonal antimelanoma-antibody/ricin-A-chain immunotoxin (ITN) on melanoma cells in multicellular tumor spheroids (MTS) as well as the penetration of ITN into MTS. For Minor melanoma cells in monolayer the ITN exerted cytotoxic effects after as little as 1 h of exposure. Increasing exposure time resulted in progressive increases in cytotoxic activity. In contrast, the cell kill effects of ITN were markedly delayed and reduced when Minor cells were in MTS. The ITN cytotoxic effects on the melanoma MTS were more than 100 fold less than those in monolayer. Patterns of ITN-induced cytotoxicities for Minor and for another melanoma cell line, DND-1A, were comparable. The native ricin A was more active against PC-10 squamous lung cancer cells than Minor cells, whereas the ITN was more cytotoxic against Minor cells than PC-10 cells, thus exhibiting selectivity. An autoradiographic study revealed time-dependent penetration of radiolabeled ITN from the surface of Minor MTS into the core. Incubation for 1 h resulted in the penetration of ITN into only the two or three outer layers of the Minor MTS, and low grain counts. Prolonged exposure resulted in inhomogeneous penetration of ITN into almost the entire melanoma MTS. Penetration of ITN into PC-10 MTS was extremely poor. The reduced cytotoxicity of ITN on melanoma cells in MTS as compared to cells grown in monolayer appears to correlate with its inhomogeneous distribution in the MTS. The delayed cytotoxicity of ITN is also consistent with its slow penetration into the core of the MTS.

Key words: Immunotoxin, Melanoma, Multicellular tumor spheroids

References

  • 1.Arnon R, Sela M. Experimental approaches to drug targeting: Targeted chemotherapy. Cancer Surv. 1982;3:429. [Google Scholar]
  • 2.Casellas P, Brown JP, Gross O, Gross P, Hellstrom I, Janser FK, Poncelet P, Roncucci R, Vidal H, Hellstrom KE. Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen P97. Int J Cancer. 1982;30:437. doi: 10.1002/ijc.2910300410. [DOI] [PubMed] [Google Scholar]
  • 3.Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J. Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res. 1986;46:3183. [PubMed] [Google Scholar]
  • 4.Fawwaz RA, Wang TST, Srivastava SC, Rosen JM, Ferrone S, Hardy MA, Alderson PU. Potential of palladium-109-labeled antimelanoma monoclonal antibody for tumor therapy. J Nucl Med. 1984;25:796. [PubMed] [Google Scholar]
  • 5.Freyer JP, Sutherland RM. Selective dissociation and characterization of cells from different regions of multicell tumor spheroids. Cancer Res. 1980;40:3956. [PubMed] [Google Scholar]
  • 6.Gilliland DG, Steplewski Z, Collier RJ, Mitchell KF, Chang TH, Koprowski H. Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci USA. 1980;77:4539. doi: 10.1073/pnas.77.8.4539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Harkonen S, Stoudemire J, Mischak R, Spitler LE, Lopez H, Scannon P. Toxicity and immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats. Cancer Res. 1987;47:1377. [PubMed] [Google Scholar]
  • 8.Hertler AA, Frankel AE. Immutoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol. 1989;7:1932. doi: 10.1200/JCO.1989.7.12.1932. [DOI] [PubMed] [Google Scholar]
  • 9.Inoue S, Tsukada T, Itoh M, Mizuno A, Takaoka K, Miyamoto H, Kawakami Y, Kobayashi H. Studies of the penetration of doxorubicin (DXR)-anti-α-fetroprotein (αAFP) conjugates intomulticellular tumor spheroids (MTS) Proc Am Assoc Cancer Res. 1987;28:426. [Google Scholar]
  • 10.Jain RF, Baxter LY. Mechanisms of heterogenous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988;48:7022. [PubMed] [Google Scholar]
  • 11.Kinjo M, Oka K, Naito S, Kohga S, Tanaka K, Oboshi S, Hayata Y, Yasumoto Thromboplastic and fibrinolytic activities of cultured human cancer cell lines. Br J Cancer. 1979;39:15. doi: 10.1038/bjc.1979.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Kohno N, Ohnuma T, Biller HF, Holland JF. Effects of cisplatin plus fluorouracil vs cisplatin plus cytarabine on head and neck squamous multicellular tumor spheroids. Arch Otolaryngol Head Neck Surg. 1988;114:157. doi: 10.1001/archotol.1988.01860140055021. [DOI] [PubMed] [Google Scholar]
  • 13.Kohno N, Ohnuma T, Kaneko M, Holland JF. Interactions of doxorubicin and cisplatin in squamous carcinoma cells in culture. Br J Cancer. 1988;58:330. doi: 10.1038/bjc.1988.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kuroki T. Colony formation of mammalian cells of agar plates and its application to Lederberg's replica plating. Exp Cell Res. 1974;80:55. doi: 10.1016/0014-4827(73)90274-7. [DOI] [PubMed] [Google Scholar]
  • 15.Kwok CS, Cole SE, Liao SK. Uptake kinetics of monoclonal antibodies by human malignant melanoma multicell spheroids. Cancer Res. 1988;48:1856. [PubMed] [Google Scholar]
  • 16.Martinex O, Kimura J, Gottfried TD, Zeicher M, Wofsy L. Variance in cytotoxic effectiveness of antibody-toxin A hybrids. Cancer Surv. 1982;1:373. [Google Scholar]
  • 17.Nederman T, Norling B, Glimelius B, Carlsson J, Brunk U. Demonstration of an extracellular matrix in multicellular tumor spheroids. Cancer Res. 1984;44:3090. [PubMed] [Google Scholar]
  • 18.Neville DM, Jr, Youle RJ. Monoclonal antibody ricin or ricin A chain hybrids: Kinetic analysis of cell killing for tumor therapy. Immunol Rev. 1982;62:75. doi: 10.1111/j.1600-065x.1982.tb00390.x. [DOI] [PubMed] [Google Scholar]
  • 19.Ohnuma T, Ohnoshi T, Tanaka T, Anderjczuk A, Holland JF, Wolman SR. Characterization and chemotherapeutic sensitivity of two malignant melanoma sublines derived from a patient. Proc Am Assoc Cancer Res Am Soc Clin Oncol. 1981;22:52. [Google Scholar]
  • 20.Ong GL, Mattes MJ. Penetration and binding of antibodies in experimental human solid tumors grown in mice. Cancer Res. 1989;49:4264. [PubMed] [Google Scholar]
  • 21.Pimm MV, Jones JA, Price MR, Middle JB, Embleton MJ, Baldwin RW. Tumor localization of monoclonal antibody against a rat mammary carcinoma and suppression of tumor growth with adriamycin-antibody conjugates. Cancer Immunol Immunother. 1982;12:125. [Google Scholar]
  • 22.Ramakrishnan S, Houston LL. Comparison of the selective cytotoxic effects of immunotoxins containing ricin A chain or pokeweed antiviral protein and anti-Thy 1.1 monoclonal antibodies. Cancer Res. 1984;44:201. [PubMed] [Google Scholar]
  • 23.Raso V, Griffin T. Specific cytotoxicity of a human immunoglobulin-directed Fab′-ricin A chain conjugate. J Immunol. 1980;125:2610. [PubMed] [Google Scholar]
  • 24.Scannon PS, Spitler LE, Lee HM, Kawahata RT, Mischak RP (1986) Human melanoma specific immunotoxins. United States Patent 4, 590, 071: May 20, 1986
  • 25.Sivam G, Pearson JW, Bohn W, Oldham RK, Sadoff JC, Morgan AC., Jr Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates. Cancer Res. 1987;47:3169. [PubMed] [Google Scholar]
  • 26.Spitler LE, Rio MD, Khentigan A, Wedel NI, Brophy NA, Miller LL, Harkonen WS, Rosendorf LL, Lee HM, Mischak RP, Kawahata RT, Stoudemire JB, Fradkin LB, Bautista EE, Scannon PI. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res. 1987;47:1717. [PubMed] [Google Scholar]
  • 27.Sutherland RM, Durand RE. Hypoxic cells in an in vitro tumor model. Int J Radiat Biol. 1973;23:235. doi: 10.1080/09553007314550261. [DOI] [PubMed] [Google Scholar]
  • 28.Sutherland R, Buchegger F, Schreyer M, Vacca A, Mach JP. Penetration and binding or radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res. 1987;47:1627. [PubMed] [Google Scholar]
  • 29.Yuhas JM, Li AP, Martinex AO, Ladman AJ. Simplified method for production and growth of multicellular tumor spheroids. Cancer Res. 1977;37:3639. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES